News

This Phase II trial was set up as a randomized, single-blind, controlled study in 140 healthy volunteers and tested the antibody product in association with Sanofi Pasteur human

According to the company, RGN-457 is based on thymosin beta 4 peptide formulated as an inhaled therapeutic agent to address the cystic fibrosis patient population. JJ Finkelstein, RegeneRx’s

Roche Diagnostics will develop its new product line for RealTime ready qPCR assays with the Universal ProbeLibrary. The financial details of the agreement including commercial milestone payments and

This capital will be utilized to support the ongoing Phase III development program evaluating linaclotide for the treatment of irritable bowel syndrome with constipation and chronic constipation, to

In addition to Smolensk, PPD has added offices in Moscow and St Petersburg, Russia, and Kiev, Ukraine, with this acquisition. Sergey Sudilovsky, currently director general of InnoPharm, will

Mr Junius also has been nominated to join the board, with this nomination to be voted upon at the company’s upcoming annual meeting of shareholders. Mitchel Sayare, currently

Delta Lloyd Levensverzekeringen has disclosed that it holds 1.14 million shares in the share capital of Galapagos, as of September 1, 2008. This is the first notification Galapagos

Under the financing, Panacea Biotec’s subsidiary has agreed to purchase approximately 3.73 million shares of PharmAthene common stock at a negotiated price of $3.50 per share, which represents

Endovascular valve edge-to-edge repair (Everest) study is an FDA-approved Phase II randomized, controlled, multi-center clinical research study in the US and Canada evaluating the safety and efficacy of